| scholarly article | Q13442814 |
| P50 | author | Alexandre Mebazaa | Q63107378 |
| Alain Cohen-Solal | Q63107424 | ||
| P2093 | author name string | Markku S Nieminen | |
| Milton Packer | |||
| Stuart J Pocock | |||
| Robert J Padley | |||
| Franz X Kleber | |||
| Matti Kivikko | |||
| Pentti Põder | |||
| Roopal Thakkar | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| heart failure | Q181754 | ||
| acute decompensated heart failure | Q4677930 | ||
| P304 | page(s) | 1883-91 | |
| P577 | publication date | 2007-05-02 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial | |
| P478 | volume | 297 |
| Q35865918 | A Randomized Blinded Study of the Left Ventricular Myocardial Performance Index Comparing Epinephrine to Levosimendan following Cardiopulmonary Bypass |
| Q37098407 | A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease |
| Q39192426 | A response-adaptive design of initial therapy for emergency department patients with heart failure |
| Q38131789 | A review of current therapies used in the treatment of congestive heart failure |
| Q98466836 | A review of the management of patients with advanced heart failure in the intensive care unit |
| Q37291720 | Acute Heart Failure Treatment |
| Q24650932 | Acute decompensated heart failure: contemporary medical management |
| Q39316738 | Acute heart failure syndromes: potential strategies to improve post-discharge outcomes |
| Q42972084 | Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? |
| Q34111247 | Acute heart failure: focusing on acute cardiogenic pulmonary oedema. |
| Q57396164 | Acute heart failure: have we got it all wrong? |
| Q57911301 | Acute heart failure: lessons learned, roads ahead |
| Q30234708 | Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. |
| Q30394479 | Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations |
| Q39158670 | Advances in chemical pharmacotherapy for managing acute decompensated heart failure |
| Q24645066 | Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond |
| Q28084239 | Agents with vasodilator properties in acute heart failure: how to design successful trials |
| Q38964211 | Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitro. |
| Q37078768 | Approach to hemodynamic shock and vasopressors |
| Q26800965 | Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review |
| Q90057040 | Atrial Cardiomyopathy: An Unexplored Limb of Virchow's Triad for AF Stroke Prophylaxis |
| Q36158310 | Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial |
| Q37019674 | Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. |
| Q42653967 | Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials |
| Q64239467 | Beyond Reperfusion: Acute Ventricular Unloading and Cardioprotection During Myocardial Infarction |
| Q33316156 | CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration |
| Q57665132 | CSI position statement on management of heart failure in India |
| Q35104231 | Calcium sensitisation impairs diastolic relaxation in post-ischaemic myocardium: implications for the use of Ca(2+) sensitising inotropes after cardiac surgery |
| Q26826988 | Calcium sensitizers: What have we learned over the last 25 years? |
| Q37873812 | Can we prevent or treat renal dysfunction in acute heart failure? |
| Q24650348 | Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials |
| Q37913110 | Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially |
| Q56485189 | Cardiogenic Shock |
| Q38217113 | Cardiohepatic syndrome: liver injury in decompensated heart failure |
| Q36865182 | Cardiorenal Syndrome Type 1: Renal Dysfunction in Acute Decompensated Heart Failure |
| Q38127668 | Cardiorenal syndrome: new developments in the understanding and pharmacologic management |
| Q37696360 | Cardiorenal syndrome: still not a defined entity |
| Q38074093 | Causes and treatment of oedema in patients with heart failure |
| Q41375244 | Cell-based delivery of dATP via gap junctions enhances cardiac contractility |
| Q28085736 | Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs |
| Q35170235 | Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry |
| Q37880858 | Chronic heart failure: current evidence, challenges to therapy, and future directions |
| Q39220435 | Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. |
| Q36862605 | Clinical pharmacology of levosimendan |
| Q35561430 | Clinical review: the ABC of weaning failure--a structured approach |
| Q37941602 | Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. |
| Q44825076 | Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. |
| Q46915198 | Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs |
| Q33613185 | Comparison of Levosimendan versus Dobutamine in Patients with Moderate to Severe Left Ventricular Dysfunction Undergoing Off-pump Coronary Artery Bypass Grafting: A Randomized Prospective Study |
| Q57178023 | Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of C |
| Q37929868 | Contemporary management and research directions in advanced heart failure: where are we going? |
| Q37076287 | Contemporary management of pediatric heart failure |
| Q38588160 | Critical care for paediatric patients with heart failure |
| Q26753862 | Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome |
| Q38009708 | Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure |
| Q26822842 | Current strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approach |
| Q35675983 | De novo acute heart failure and acutely decompensated chronic heart failure |
| Q36931450 | Decompensated heart failure |
| Q48283568 | Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials? |
| Q46143451 | Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction |
| Q43711626 | Do inotropes really have a future? |
| Q37967364 | Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials |
| Q34209528 | Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study |
| Q84627320 | Drug-induced atrial fibrillation |
| Q88599261 | Drugs' development in acute heart failure: what went wrong? |
| Q34830023 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology |
| Q55050673 | ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology |
| Q35057622 | Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group |
| Q27000455 | Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group |
| Q38372545 | Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial. |
| Q83091387 | Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial |
| Q48126541 | Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction |
| Q36396523 | Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials. |
| Q46050849 | Effects of intravenous and inhaled levosimendan in severe rodent sepsis |
| Q38292123 | Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis |
| Q48263954 | Effects of levosimendan on heart failure in normotensive patients: does loading dose matter? |
| Q37435182 | Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure |
| Q36473847 | Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients |
| Q37240303 | Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF |
| Q37343857 | Effects of tolvaptan on dyspnoea relief from the EVEREST trials |
| Q50060231 | Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. |
| Q48073496 | Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial |
| Q36178408 | Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events |
| Q38694200 | Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype? |
| Q37670190 | Emerging drugs for acute myocardial infarction |
| Q37516738 | End points for clinical trials in acute heart failure syndromes |
| Q27012843 | End points for comparative effectiveness research in heart failure |
| Q37812007 | Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure |
| Q90166417 | Epinephrine, inodilator, or no inotrope in venoarterial extracorporeal membrane oxygenation implantation: a single-center experience |
| Q33917887 | GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study |
| Q57628656 | Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction† |
| Q33754315 | Half-molar sodium lactate infusion improves cardiac performance in acute heart failure: a pilot randomised controlled clinical trial |
| Q38734235 | Heart failure in patients admitted for acute coronary syndromes: A report from a large national registry. |
| Q42835997 | Heart failure update 2010 and current ESC guidelines |
| Q54737397 | Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure. |
| Q92454801 | Hurdles to Cardioprotection in the Critically Ill |
| Q37653092 | Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity i |
| Q96690460 | In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department |
| Q42198249 | Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart |
| Q41034753 | Initial Observations of the Effects of Calcium Chloride Infusions in Pediatric Patients with Low Cardiac Output |
| Q43241638 | Initial experience with levosimendan infusion for preoperative management of hypoplastic left heart syndrome |
| Q38061473 | Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option? |
| Q24201225 | Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome |
| Q47707958 | Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome |
| Q42907027 | Inotropic therapy for end-stage heart failure patients |
| Q37412632 | Integration of medical therapy and mechanical circulatory support in the management of acute heart failure |
| Q40780801 | Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. |
| Q85976525 | Intermittent inotrope therapy: evidence or belief? |
| Q38173852 | Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials |
| Q43961914 | Intermittent levosimendan treatment in patients with severe congestive heart failure |
| Q54029634 | Intravenous inotropic agents in heart failure. |
| Q33750399 | Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers |
| Q39750299 | Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction. |
| Q61632651 | Is Protein Kinase C Inhibition the Tip of the Iceberg in New Therapeutics for Acutely Decompensated Heart Failure? |
| Q43119695 | Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence? |
| Q94566824 | Istaroxime in acute heart failure: the holy grail is at HORIZON? |
| Q37399996 | Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? |
| Q39908647 | Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording |
| Q97884755 | Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use |
| Q37352397 | Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure |
| Q46219963 | Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction |
| Q42602858 | Levosimendan decreases intracranial pressure after hypothermic circulatory arrest in a porcine model |
| Q36549253 | Levosimendan does not improve survival time in a rat model of verapamil toxicity |
| Q51760678 | Levosimendan for Perioperative Cardioprotection: Myth or Reality? |
| Q46479123 | Levosimendan for bridging in a pediatric patient with Alström syndrome awaiting heart-lung transplantation. |
| Q41226308 | Levosimendan improves exercise performance in patients with advanced chronic heart failure. |
| Q58605947 | Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application |
| Q38191912 | Levosimendan in critical illness: a literature review. |
| Q89443434 | Levosimendan in pulmonary hypertension and right heart failure |
| Q46056920 | Levosimendan in the emergency department: a useful tool to improve cellular perfusion |
| Q45114588 | Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial |
| Q26765449 | Levosimendan meta-analyses: Is there a pattern in the effect on mortality? |
| Q34139035 | Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction |
| Q36832816 | Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials |
| Q24650903 | Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE |
| Q24629274 | Levosimendan: current data, clinical use and future development |
| Q46186787 | Levosimendan: from basic science to clinical practice |
| Q38734731 | Long-term intravenous inotropes in low-output terminal heart failure? |
| Q49487211 | Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. |
| Q37765876 | Loop diuretic therapy in heart failure: the need for solid evidence on a fluid issue. |
| Q91841513 | Management of Cardiogenic Shock in a Cardiac Intensive Care Unit |
| Q27028203 | Management of the cardiorenal syndrome in decompensated heart failure |
| Q36980470 | Management strategies for stage-D patients with acute heart failure |
| Q56032252 | Managing acute pulmonary oedema |
| Q57396286 | Medical management of advanced heart failure |
| Q37920401 | Medical therapy for chronic heart failure |
| Q90753855 | Mega-trials in heart failure: effects of dilution in examination of new therapies |
| Q40710330 | Mineralocorticoid Receptor Antagonism in Acute Heart Failure |
| Q37390754 | Modern approach to the treatment of decompensated heart failure |
| Q39188101 | Modern drug therapy in cardiovascular intensive care medicine |
| Q38815451 | Molecular and Digital Biomarker Supported Decision Making in Clinical Studies in Cardiovascular Indications |
| Q37880500 | Narrative review: the management of acute decompensated heart failure |
| Q49689341 | New Insights in Cardiac Calcium Handling and Excitation-Contraction Coupling. |
| Q46885804 | New pharmacological treatment approaches to cardiogenic shock |
| Q37403197 | Newer treatments for decompensated heart failure: focus on levosimendan |
| Q38225739 | Newest additions to heart failure treatment |
| Q36964682 | Novel cardiac myosin activators for acute heart failure. |
| Q38073647 | Novel pharmacologic therapies in development for acute decompensated heart failure |
| Q37893956 | Novel therapeutic targets for the treatment of heart failure. |
| Q57316359 | Omecamtiv mecarbil: a promising new drug in systolic heart failure |
| Q38409693 | Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study |
| Q38572099 | Oral levosimendan in patients with severe chronic heart failure --the PERSIST study |
| Q39756284 | Outcomes of acute heart failure associated with acute coronary syndrome versus other causes |
| Q37086309 | Overview of emerging pharmacologic agents for acute heart failure syndromes |
| Q37552943 | Overview of emerging pharmacotherapy in chronic heart failure |
| Q48095229 | Pathophysiology of acute heart failure syndrome: a knowledge gap. |
| Q37089975 | Pharmacologic Management of the Cardio-renal Syndrome |
| Q26781777 | Pharmacologic agents for acute hemodynamic instability: recent advances in the management of perioperative shock- a systematic review |
| Q37929864 | Pharmacologic therapy for New York Heart Association class IV heart failure |
| Q39249844 | Pharmacological and Non-pharmacological Treatment for Decompensated Heart Failure: What Is New? |
| Q39740830 | Pharmacological management of cardiorenal syndromes |
| Q37236713 | Pharmacological optimization of tissue perfusion |
| Q38122297 | Pharmacological treatment of acute heart failure: current treatment and new targets |
| Q38099679 | Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. |
| Q37821626 | Pharmacotherapy for acute heart failure syndromes |
| Q36906123 | Phase II trials in heart failure: the role of cardiovascular imaging |
| Q36982705 | Positive inotropes in heart failure: a review article |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q39328224 | Preconditioning with levosimendan before implantation of left ventricular assist devices |
| Q37390743 | Prevalence of anemia in heart failure and its effects on prognosis |
| Q90291774 | Primary graft dysfunction after heart transplantation: a thorn amongst the roses |
| Q45904891 | Progress or lack of progress in hospitalized heart failure. |
| Q88711524 | Pulmonary Oedema-Therapeutic Targets |
| Q37314355 | Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study |
| Q37154191 | Rationale and design of the multicenter randomized trial investigating the effects of levosimendan pretreatment in patients with low ejection fraction (≤40 %) undergoing CABG with cardiopulmonary bypass (LICORN study). |
| Q43190664 | Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study). |
| Q94585840 | Reappraisal on pharmacological and mechanical treatments of heart failure |
| Q38737940 | Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations |
| Q57822514 | Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure |
| Q38220684 | Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure? |
| Q39195160 | Redefining the role of biomarkers in heart failure trials: expert consensus document |
| Q48187672 | Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials |
| Q51181204 | Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. |
| Q35566683 | Renal dysfunction in acute heart failure |
| Q26781936 | Renocardiac syndromes: physiopathology and treatment stratagems |
| Q44389489 | Rescuing a failing heart: putting on the squeeze |
| Q36302339 | Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure. |
| Q37537154 | Role of guanylate cyclase modulators in decompensated heart failure |
| Q33816527 | Role of inotropic agents in the treatment of heart failure. |
| Q37176415 | Role of tolvaptan in acute decompensated heart failure |
| Q55041662 | Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. |
| Q35687065 | Sepsis-induced cardiomyopathy |
| Q38215304 | Serelaxin : a potential new drug for the treatment of acute heart failure |
| Q37711521 | Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial |
| Q34310960 | Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial |
| Q90446344 | Shock - Classification and Pathophysiological Principles of Therapeutics |
| Q88711670 | Shock Management for Cardio-surgical Intensive Care Unit Patient: The Silver Days |
| Q42949755 | Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure |
| Q58814233 | Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods |
| Q28607749 | Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs |
| Q34323758 | Structure and function of coagulogen, a clottable protein in horseshoe crabs |
| Q24236592 | Structured telephone support or telemonitoring programmes for patients with chronic heart failure |
| Q39003251 | Structures reveal details of small molecule binding to cardiac troponin |
| Q39200790 | Systolic Blood Pressure on Admission and Mortality in Patients Hospitalized With Acute Heart Failure: Observations From the Gulf Acute Heart Failure Registry. |
| Q28260629 | Targeting the sarcomere to correct muscle function |
| Q43178435 | Telemonitoring for heart failure: the only feasible option for good universal care? |
| Q34340391 | The cardiorenal syndrome: making the connection |
| Q37935779 | The challenge of treating congestion in advanced heart failure |
| Q47212291 | The clinical effects of levosimendan are not attenuated by sulfonylureas |
| Q38072257 | The disconnect between phase II and phase III trials of drugs for heart failure |
| Q35006812 | The effects of levosimendan and dobutamine in experimental bupivacaine-induced cardiotoxicity. |
| Q51066753 | The effects of levosimendan on renal function early after heart transplantation: results from a pilot randomized trial. |
| Q39296001 | The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study |
| Q47097922 | The inodilator levosimendan as a treatment for acute heart failure in various settings. |
| Q47156435 | The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure |
| Q47158526 | The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure |
| Q42086761 | The relationship between inotrope exposure, six-hour postoperative physiological variables, hospital mortality and renal dysfunction in patients undergoing cardiac surgery |
| Q26745542 | The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion |
| Q38034549 | The role of natriuretic peptides: from the emergency department throughout hospitalization |
| Q37523958 | The role of nesiritide in heart failure |
| Q35835748 | The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy |
| Q92158470 | Therapeutic Advances in the Management of Acute Decompensated Heart Failure |
| Q38267665 | Therapeutic adjustments in stage D heart failure: challenges and strategies |
| Q104137178 | Time-sensitive approach in the management of acute heart failure |
| Q37354429 | Timing and duration of interventions in clinical trials for patients with hospitalized heart failure |
| Q33973976 | Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome |
| Q84535250 | Treatment of acute heart failure using levosimendan for a patient with dilated cardiomyopathy, chronic renal failure, and hypertension |
| Q41104057 | Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011. |
| Q53719697 | Understanding the differences among inotropes. |
| Q60928393 | Update on heart failure management and future directions |
| Q46790124 | Update on inotropic therapy in the management of acute heart failure |
| Q39258163 | Update on the Management of Acute Decompensated Heart Failure |
| Q92766824 | Use of Impella heart pump for management of women with peripartum cardiogenic shock |
| Q26774435 | Use of Inotropic Agents in Treatment of Systolic Heart Failure |
| Q36147248 | Use of inotropes and vasopressor agents in critically ill patients. |
| Q37858515 | Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents |
| Q92236838 | Use of levosimendan in acute and advanced heart failure: short review on available real-world data |
| Q59789293 | Use of levosimendan in acute heart failure |
| Q35767495 | Use of levosimendan in patients with heart failure in different settings: case reports and treatment guidance. |
| Q37466325 | Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion |
| Q88915069 | Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan |
| Q37811626 | Vasoactive drugs in circulatory shock |
| Q37355110 | Vasodilators in the treatment of acute heart failure: what we know, what we don't |
| Q51756509 | Weaning from inotropic support and concomitant beta-blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis. |
| Q26771479 | What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? |
| Q37793527 | What causes a broken heart--molecular insights into heart failure |
| Q38123740 | What's new in the treatment of acute heart failure? |
| Q92588956 | Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials |
| Q54716857 | [Acute and chronic heart failure in light of the new ESC guidelines]. |
| Q83250047 | [Advances in heart failure] |
| Q49835894 | [Cardiogenic shock : Current evidence]. |
| Q83695863 | [Cardiogenic shock] |
| Q86312717 | [Cardiogenic shock] |
| Q83474581 | [Dobutamine in severe heart failure. More questions than answers] |
| Q87499438 | [Essential cardiac biomarkers in myocardial infarction and heart failure] |
| Q89931262 | [Levosimendan-no effect on multiorgan failure in septic shock] |
| Q87853456 | [New options in the treatment of acute heart failure] |
| Q53603789 | [Treatment of acute heart failure]. |
Search more.